Lexicon Pharmaceuticals, Inc. (LXRX) Announces Positive Phase I Trial of LX1031 for Irritable Bowel Syndrome
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), a biopharmaceutical company that focuses on discovering and developing breakthrough treatments for various human disease,…